These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36333234)

  • 1. Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?
    Kirkham AM; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Cytotherapy; 2023 Mar; 25(3):341-352. PubMed ID: 36333234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval.
    Kirkham AM; Bailey AJM; Monaghan M; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Stem Cells Transl Med; 2022 Jul; 11(7):675-687. PubMed ID: 35758400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19.
    Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Cytotherapy; 2022 Jun; 24(6):639-649. PubMed ID: 35219584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
    Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
    Lu W; Yan L; Tang X; Wang X; Du J; Zou Z; Li L; Ye J; Zhou L
    J Transl Med; 2024 Jun; 22(1):550. PubMed ID: 38851730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.
    Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F
    Front Immunol; 2023; 14():1200180. PubMed ID: 37415976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
    Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
    Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
    Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
    Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
    J Infect Public Health; 2022 Aug; 15(8):896-901. PubMed ID: 35849852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
    Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V
    Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications.
    Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L
    Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence-FAST Evidence.
    Liao G; Zheng K; Lalu MM; Fergusson DA; Allan DS
    Transfus Med Rev; 2020 Jul; 34(3):165-171. PubMed ID: 32684483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
    Chen L; Qu J; Kalyani FS; Zhang Q; Fan L; Fang Y; Li Y; Xiang C
    Cell Mol Life Sci; 2022 Feb; 79(3):142. PubMed ID: 35187617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.